TY - JOUR
T1 - The Effect of the Drug Medi-Cal Organized Delivery System 1115 Demonstration Waiver on Substance Use Disorder Treatment Access
T2 - Evidence from California
AU - Bass, Brittany
AU - Urada, Darren
AU - Khurana, Dhruv
AU - Boustead, Anne
AU - Joshi, Vandana
N1 - Funding Information:
The authors would like to thank Howard Padwa, Valerie Antonini, Anne Lee, Elise Tran, Cheryl Teruya, and David Huang for their excellent comments on earlier drafts. Financial support from the CA Department of Health Care Services is also acknowledged.
Funding Information:
The authors would like to thank Howard Padwa, Valerie Antonini, Anne Lee, Elise Tran, Cheryl Teruya, and David Huang for their excellent comments on earlier drafts. Financial support from the CA Department of Health Care Services is also acknowledged. None. ☆ The authors would like to thank Howard Padwa, Valerie Antonini, Anne Lee, Elise Tran, Cheryl Teruya, and David Huang for their excellent comments on earlier drafts. Financial support from the CA Department of Health Care Services is also acknowledged.
Publisher Copyright:
© 2023 The Authors
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Background: In August 2015, the California Department of Health Care Services created the Drug Medi-Cal Organized Delivery System 1115 demonstration waiver (DMC-ODS waiver) to improve service delivery to Medi-Cal-eligible individuals with a substance use disorder (SUD). We examine if implementing the DMC-ODS waiver across California counties improved patient access to SUD treatment services. Methods: We use administrative data from 2016 to 2020 from a reporting system for all publicly-funded SUD treatment services delivered in California and employ difference-in-differences and event study empirical strategies exploiting the differential timing of DMC-ODS waiver adoption across counties. Results: Event study analyses show that eleven or more months after the introduction of the DMC-ODS waiver, the number of unique patient admissions significantly increase by nearly 20%. Residential treatment admissions significantly increase by roughly 25% in all months post-waiver introduction. Conclusions: This study provides valuable information for policymakers about implementing 1115 waivers, and the important public health implications. California's DMC-ODS waiver has demonstrated that 1115 waivers similar to it can likely increase access to SUD treatment.
AB - Background: In August 2015, the California Department of Health Care Services created the Drug Medi-Cal Organized Delivery System 1115 demonstration waiver (DMC-ODS waiver) to improve service delivery to Medi-Cal-eligible individuals with a substance use disorder (SUD). We examine if implementing the DMC-ODS waiver across California counties improved patient access to SUD treatment services. Methods: We use administrative data from 2016 to 2020 from a reporting system for all publicly-funded SUD treatment services delivered in California and employ difference-in-differences and event study empirical strategies exploiting the differential timing of DMC-ODS waiver adoption across counties. Results: Event study analyses show that eleven or more months after the introduction of the DMC-ODS waiver, the number of unique patient admissions significantly increase by nearly 20%. Residential treatment admissions significantly increase by roughly 25% in all months post-waiver introduction. Conclusions: This study provides valuable information for policymakers about implementing 1115 waivers, and the important public health implications. California's DMC-ODS waiver has demonstrated that 1115 waivers similar to it can likely increase access to SUD treatment.
KW - 1115 waiver
KW - Residential treatment
KW - Substance use disorder treatment
KW - Substance use disorder treatment access
UR - http://www.scopus.com/inward/record.url?scp=85151268334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151268334&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2023.109847
DO - 10.1016/j.drugalcdep.2023.109847
M3 - Article
C2 - 37001321
AN - SCOPUS:85151268334
SN - 0376-8716
VL - 246
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
M1 - 109847
ER -